Gotistobart (ONC-392) for Non-small cell lung cancer (NSCLC) that has progressed after treatment with PD-1/PD-L1 inhibitors
OncoC4, Inc.
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT05671510 on ClinicalTrials.gov →Study type
interventional
Design
Randomized, open-label, parall…
Target enrollment
630
Est. completion
2027-08-31
Investor scorecard
Probability of success
moderate
Timeline to catalyst
The trial is expected to complete in August 2027. Primary analysis may occur earlier if the trial meets its endpoints at an interim analysis. Investors should expect data readout around 2026-2027.
Potential stock impact
SignificantThe trial is well-designed and addresses an unmet need. However, the historical success rate for phase 3 trials in oncology is around 50-60%. Gotistobart has shown promising early data, but it is competing against docetaxel, which is an active comparator. The primary endpoint of overall survival is a high bar, and many drugs have failed to show improvement in this setting. Additionally, the safety profile of CTLA-4 inhibitors is a concern, and the trial is open-label, which can introduce bias. Overall, a moderate probability of success is reasonable.
What is being tested?
This trial is testing a new drug called gotistobart (also known as ONC-392) in patients with a type of lung cancer called non-small cell lung cancer (NSCLC). These patients have already been treated with drugs called PD-1/PD-L1 inhibitors (like Keytruda or Opdivo), but their cancer has gotten worse. Gotistobart is a type of immunotherapy that works differently from PD-1 inhibitors. It targets a protein called CTLA-4, which acts as a brake on the immune system. By blocking CTLA-4, gotistobart aims to reactivate immune cells to attack the cancer. The trial compares gotistobart to docetaxel, a standard chemotherapy drug often used in this situation. The goal is to see if gotistobart helps patients live longer than docetaxel.
How does the trial work?
This is a phase 3 trial, which means it is a large study designed to confirm whether a new treatment is better than the current standard. Patients are randomly assigned (like flipping a coin) to receive either gotistobart or docetaxel. The trial is 'open-label', meaning both the doctors and patients know which treatment they are getting. Patients receive treatment until their cancer progresses or they experience unacceptable side effects. The trial is being conducted at multiple sites around the world. The main measure of success is overall survival, which is how long patients live after starting treatment. The trial will also track how many patients have their tumors shrink, how long they live without the cancer growing, and what side effects occur. The trial is currently not recruiting new patients, meaning it is already underway and following existing participants.
What does success look like?
Success in this trial would be if patients receiving gotistobart live significantly longer than those receiving docetaxel. In previous studies, docetaxel typically provides a median overall survival of around 8-10 months in this patient population. For gotistobart to be considered a success, it would need to show a meaningful improvement, such as a median overall survival of 12 months or more, with a statistically significant difference. Additionally, the trial will look at whether gotistobart has a manageable side effect profile. If the trial meets its primary endpoint of improving overall survival, it could lead to regulatory approval and establish gotistobart as a new treatment option for these patients.
What it means for investors
For investors, this trial is a major catalyst for OncoC4, the company developing gotistobart. If the trial is successful, it could lead to regulatory approval and significant revenue, as NSCLC is a large market. The trial is expected to complete in 2027, so data may be available around that time. Positive results could cause OncoC4's stock to rise significantly, potentially making it a takeover target for larger pharmaceutical companies. However, if the trial fails, the stock could drop sharply. Investors should also consider that the trial is being conducted in a competitive landscape, with other drugs like nivolumab plus ipilimumab (Opdivo + Yervoy) and other CTLA-4 inhibitors in development. The outcome of this trial will be a key determinant of OncoC4's future prospects.
Trial endpoints
Primary endpoints
Secondary endpoints
Comparator
Docetaxel (standard chemotherapy)
Competitive landscape
The market for second-line treatment of NSCLC after PD-1/PD-L1 inhibitor progression is substantial. Approximately 30-40% of NSCLC patients receive PD-1 inhibitors as first-line therapy, and many will eventually progress. The global NSCLC therapeutics market is expected to exceed $30 billion by 2027. In the second-line setting, docetaxel has been the standard for years, but new options are needed. If gotistobart demonstrates improved survival, it could capture a significant share of this market, potentially reaching peak sales of $1-2 billion annually.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Nivolumab + Ipilimumab (Opdivo + Yervoy) | Bristol-Myers Squibb | Phase 1 | Combination of PD-1 and CTLA-4 inhibitors, already approved for certain NSCLC patients, but not specifically for post-PD-1 progression. |
| Sitravatinib | Mirati Therapeutics | Phase 1 | A multi-kinase inhibitor that targets TAM receptors, being tested in combination with PD-1 inhibitors in post-PD-1 progression. |
| BI 754091 | Boehringer Ingelheim | Phase 1 | An anti-PD-1 antibody being tested in combination with other agents for patients who progressed on prior PD-1 therapy. |
Historical context
Prior trial results
Gotistobart (ONC-392) has been studied in earlier phase trials. In a phase 1/2 study (NCT03860272), it showed promising activity in patients with advanced solid tumors, including NSCLC, who had progressed on prior immunotherapy. The drug demonstrated a manageable safety profile and evidence of anti-tumor activity, with some patients achieving durable responses. These results supported the initiation of this phase 3 trial.
Regulatory history
As of now, gotistobart has not received any special designations like fast track or breakthrough therapy from the FDA. The phase 3 trial is ongoing, and no regulatory decisions have been made.
Similar drug precedents
Ipilimumab (Yervoy), a CTLA-4 inhibitor, was the first in its class and is approved for melanoma and certain lung cancers. However, it has a high rate of immune-related side effects. Other CTLA-4 inhibitors like tremelimumab (from AstraZeneca) have had mixed results in lung cancer. The success of ipilimumab in combination with nivolumab in NSCLC suggests that CTLA-4 inhibition can be effective, but safety is a concern. Gotistobart is designed to be a 'next-generation' CTLA-4 inhibitor that may have fewer side effects while maintaining efficacy.